Zdravlje A.D. (Zdravlje) announces the signing of a license agreement with the Medicines Patent Pool (MPP) for a generic version of nirmatrelvir, the novel oral COVID-19 antiviral medicine, developed by Pfizer, which is administered in combination with low dose ritonavir.

This sub-license agreement is the outcome of a licensing agreement signed between MPP and Pfizer in November 2021 to facilitate affordable global access to nirmatrelvir; ritonavir.